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ABSTRACT
Fatty Acid Synthase (FASN), a key enzyme of de novo lipogenesis, is upregulated
in many cancers including colorectal cancer (CRC); increased FASN expression is
associated with poor prognosis. Potent FASN inhibitors (TVBs) developed by 3-V
Biosciences demonstrate anti-tumor activity in vitro and in vivo and a favorable
tolerability profile in a Phase I clinical trial.
However, CRC characteristics associated with responsiveness to FASN inhibition
are not fully understood. We evaluated the effect of TVB-3664 on tumor growth in
nine CRC patient-derived xenografts (PDXs) and investigated molecular and metabolic
changes associated with CRC responsiveness to FASN inhibition.
CRC cells and PDXs showed a wide range of sensitivity to FASN inhibition. TVB3664 treatment showed significant response (reduced tumor volume) in 30% of
cases. Anti-tumor effect of TVB-3664 was associated with a significant decrease in a
pool of adenine nucleotides and alterations in lipid composition including a significant
reduction in fatty acids and phospholipids and an increase in lactosylceramide and
sphingomyelin in PDXs sensitive to FASN inhibition. Moreover, Akt, Erk1/2 and AMPK
were major oncogenic pathways altered by TVBs.
In summary, we demonstrated that novel TVB inhibitors show anti-tumor
activity in CRC and this activity is associated with a decrease in activation of Akt
and Erk1/2 oncogenic pathways and significant alteration of lipid composition of
tumors. Further understanding of genetic and metabolic characteristics of tumors
susceptible to FASN inhibition may enable patient selection and personalized
medicine approaches in CRC.
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INTRODUCTION

tumor tissues is associated with a significant decrease in
the pool of adenine nucleotides (AXP) which play a crucial
role in a variety of metabolic functions of proliferating
cells [17]. Moreover, TVB-3664 treatment significantly
decreased the abundance of FA and phospholipids such
as phosphatidylcholines and phosphatidic acids and
significantly increased the levels of lactosylceramide and
sphingomyelin in analyzed PDX models.
Together, our findings provide evidence of
biological activity of TVB compounds in CRC and warrant
further investigation to understand the mechanisms of
resistance to FASN inhibition and improve efficacy of
FASN-targeted therapy.

Colorectal cancer (CRC) is the 2nd most common
cause of cancer death in the United States [1]. Despite
advances in our understanding of the molecular basis of
CRC and the increasing number of targeted therapies,
treatment frequently remains disappointing, particularly
for advanced stages of disease [2, 3]. New approaches
to treat advanced CRC are urgently needed to improve
clinical outcomes.
Metabolic reprogramming is a hallmark of cancer,
controlling various aspects of malignant development and
progression. Activation of de novo lipogenesis in cancer
cells, which is increasingly recognized as one of the
characteristics of aggressive cancers [4], correlates with a
poorer prognosis and shorter disease-free survival in many
tumor types including CRC [5, 6].
Abnormally elevated de novo lipogenesis provides
cancer cells with membrane building blocks, signaling
lipid molecules, and posttranslational modifications
of proteins, as well as energy to support rapid cell
proliferation [7]. Our published studies demonstrate an
increase in expression of fatty acid synthase (FASN), a
key enzyme of de novo lipogenesis, with advancing stages
of CRC, suggesting an important role of de novo lipid
synthesis in progression of this disease [6, 8].
The tumor-associated expression of FASN and its
pro-tumorigenic functions characterized in multiple studies
make this enzyme an attractive target for anti-cancer
therapy [5–7, 9]. In recent years, several compounds have
been reported to inhibit the enzymatic activity of FASN
and reduce growth of malignant cells; however, some of
them exhibit pharmacological limitations or induce weight
loss, preventing their development as systemic drugs
[9, 10]. In contrast, potent FASN inhibitors developed by
3-V Biosciences demonstrate anti-tumor activity in vitro
and in vivo and a favorable tolerability profile in a Phase
I clinical trial in patients bearing solid tumors [4, 11, 12].
The effect of FASN inhibitors on CRC progression and
CRC characteristics associated with responsiveness to
FASN inhibition are not yet known.
Patient-derived xenograft (PDX) models including
CRC PDXs retain the intratumoral clonal heterogeneity,
tumor microenvironment, and morphology of the parent
tumor through passages in mice [2, 13–15] and are one of
the most valuable models for preclinical drug evaluation
[16]. In this study, we tested the effect of TVB-3664 and
its analogs (3V-Biosciences) on tumor growth in nine CRC
PDX models, primary CRC cells, and established CRC cell
lines. We demonstrated that CRC PDXs and CRC cells
show a wide range of sensitivity to FASN inhibition and
that high levels of FASN expression are associated with
increased sensitivity of cancer cells to TVB inhibitors in
vitro. Furthermore, our results suggest that Akt, Erk1/2 and
AMPK are major oncogenic pathways altered by FASN
inhibitors. Finally, we showed that FASN inhibition in PDX
www.oncotarget.com

RESULTS
TVB inhibitors show anti-tumor activity in
established CRC cell lines and primary CRC
cells
FASN and de novo lipogenesis, its cognate
pathway, are critical components of tumor cell survival
and proliferation for a wide range of cancers [18]. Recent
studies showed that TVB-3166—an orally available,
reversible, potent, and selective FASN inhibitor—
decreases viability in multiple tumor cell lines from
solid and hematopoietic tumor types and tumor growth
of patient-derived non-small-cell lung cancer xenograft
tumors [12]. To evaluate the effect of this inhibitor in
CRC, a panel of 13 CRC cell lines was treated with 0.2 μM
of TVB-3166 for 7 days with medium and drug change
on day 4 and cellular proliferation assessed by cell count.
The CRC cell lines exhibited a wide range of sensitivity
to FASN inhibition, with low expression of FASN in
SW480, SW620 and LIM2405 associated with resistance
to FASN inhibition. Increased resistance of CRC cells
to FASN inhibition appears to be associated with an
increase in basal level of activation of pAkt and pAMPK.
Furthermore, a subset of cell lines sensitive to TVB-3166
showed enrichment in the cell lines with a high level of
active beta-catenin (Figure 1A). Similar responses were
observed when CaCo2, HT29 and LIM2405 cells were
treated with TVB-3664 and TVB-3693, analogs of TVB3166, in cell line specific medium supplemented with
10% FBS for 7 days without medium change (Figure 1B;
Supplementary Figure 1A). In comparison, the increase
in efficacy of FASN inhibitors was due to culturing cells
without a medium change, suggesting that an availability
of exogenous FAs may in part compensate for the effect of
these inhibitors on cellular proliferation. Consistent with
our previous findings using shRNA-mediated knockdown
of FASN [6], pharmacological inhibition of FASN with
TVB-3166 induced apoptosis in HCT116 and HT29 cells
(Supplementary Figure 1B) suggesting that TVB inhibitors
have cytotoxic effect on CRC cells.
24788
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To further evaluate the effect of FASN inhibition in
CRC, we treated two primary cell lines (Pt 93 and Pt 130)
established from PDX tumors [19] with different doses of
TVB-3166, TVB-3664 and TVB-3693. Primary CRC cells
used in this study were established from PDX tumors and
were used as 2D cultures (Supplementary Figure 1C–1D).
We observed a significant decrease in cellular
proliferation in both cell lines (Figure 1C and 1E).
However, the response to FASN inhibition was more
prominent in the Pt 93 cells and associated with a significant
decrease in expression of active β-catenin, c-Myc,
survivin and induction of PARP cleavage (Figure 1D).

No changes in pAkt and pAMPK were observed due
to TVB treatment in this cell line. In contrast, FASN
inhibition in Pt 130 cells lead to activation of pAMPK and
pAkt pathways as well as an increase in active β-catenin
(Figure 1F). These data further suggest that activation of
Akt and AMPK pathways can be associated with reduced
sensitivity to FASN inhibition in CRC cells.
These data demonstrate that TVB inhibitors have
anti-tumor activity in CRC and suggest that the level of
FASN expression and the activity of oncogenic pathways
such as Akt and AMPK may determine the responsiveness
of CRC to FASN inhibition.

Figure 1: CRC cell lines exhibit a wide range of sensitivity to FASN inhibition. (A) A panel of CRC cell lines was treated

with TVB-3166 (0.2 μM) for 7 days in their normal medium supplemented with 10% FBS. Medium and drug were changed on day 4.
Proliferation was determined by cell count. Data shown as percent response to FASN inhibition. (B) The two most sensitive (CaCo2 and
HT29) and the most resistant (LIM2405) cell lines were treated with multiple concentrations of TVB-3664 for 7 days without medium
change and the number of cells was counted (*p < 0.05). (C, E) Primary CRC cells Pt 93 and Pt 130 were treated with multiple concentrations
of TVBs for 7 days and proliferation was determined by cell count. *p < 0.05. (D, F) Primary CRC cells were treated for 24 h (Pt 93) and
7 days (Pt 93 and Pt 130) with TVB inhibitors and cell lyses were subjected to western blot analysis.
www.oncotarget.com
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PDXs show a wide range of sensitivity to FASN
inhibition

PDXs (Figure 2E). Consistent with the previous report that
TVB compounds are well tolerated in vivo [12], we did not
observe any drug-related toxicity in our animal studies.
With the exception of the Pt 2402 model, no significant
weight loss was noted at the end of the treatment period
(Figure 2C–2E).
We did not observe clear correlation between levels
of FASN expression in patient tissues and the response
to FASN inhibition. However, similar to in vitro studies
(Figure 1), low expression of FASN in Pt 2377PT and
LM was associated with resistance to FASN inhibition.
Interestingly, Pt 2377PT and LM PDXs showed an adverse
effect to long-term treatment with TVB-3664; however,
these changes were not significant in Pt 2377PT. We noted
that Pt 2377PT and LM models have co-existing KRAS
and PI3KCA mutations (Figure 2E, Table 1). The PI3KCA
mutation was also present in Pt 2387, which developed
resistance during treatment (Figure 2D, Table 1). TP53
mutation was present in PDX models that were sensitive
to FASN inhibition (Table 1). Even though we did
not determine significant correlation between tumor
mutational backgrounds and response to FASN inhibition,
these findings will be tested in future studies.
Together, these findings suggest that TVB-3664 as
a monotherapy has anti-tumor activity in CRC; however,
studies with a larger number of cases are required to
establish reliable biomarkers to identify a population of
patients that is sensitive to FASN-targeted therapy.

Expression of FASN is significantly upregulated
in a stage-dependent manner in CRC [6]. To evaluate the
expression of FASN in a population of patients treated at
the University of Kentucky, we analyzed FASN expression
in matched normal colon mucosa and tumor tissues from
56 patients with Stage I-IV CRC who had surgery at UK
Chandler Medical Center. The tissue microarray results
demonstrated that 9% of cases were negative for FASN
expression in tumor tissues and 91% of tumors had a
significant increase in FASN expression (Supplementary
Figure 2A).
TVB-3166 inhibits tumor growth of patientderived non-small-cell lung cancer xenograft tumors
[12, 20]. To evaluate the effect of TVB-3664, a newer
analog of TVB-3166 [20], in CRC, we established
nine CRC PDX models in NOD-SCID-IL2rg-/- (NSG)
mice using specimens collected from patients who had
undergone surgery for resection of primary CRC or
CRC metastasis (Figure 2A). Pt 2377PT/Pt 2377LM
and Pt 2449PT/Pt 2449LM models represent matching
primary tumor (PT) and liver metastasis (LM) tissues
collected from the same patient and established in NSG
mice (Supplementary Table 1). PDX models established
from patient tissues were designated generation 0 (G0);
subsequent generations established through propagation
of tumor tissues from mouse to mouse were designated
G1 and G2. Consistent with previous reports [13, 21],
the morphology of established CRC PDXs resembled
the morphology of the parent tumor through passaging in
mice (Supplementary Figure 2B–2C). To ensure that PDX
models and established primary cells recapitulate genetic
characteristics of patient tumors, the mutational status
of 198 oncogenes was analyzed in patient tissues, PDX
tissues and primary cells using next-generation sequencing
(Table 1 and Supplementary Table 2).
Immunohistological analysis of patient tumor
tissues showed that all cases were positive for FASN
expression, with the lowest expression observed in Pt
2377PT and LM (Figure 2B). Similar to our in vitro
data (Figure 1), PDX models exhibited a wide range of
sensitivity to FASN inhibition. TVB-3664 treatment led
to a significant reduction in tumor volume and tumor
weight in Pt 2614, Pt 2449PT, and Pt 2402 PDX models,
with an average reduction in tumor weight of 30%, 37.5%
and 51.5%, respectively (Figure 2C). Interestingly, TVB3664 treatment of the Pt 2387 model led to a significant
35% decrease in tumor volume at week 4 followed by
resistance, which developed at week 5. A small decrease
in tumor volume and tumor size was observed in Pt
2449LM, Pt 2568, and Pt 2607 PDX models treated
with TVB-3664, but these changes were not significant
(Figure 2C, 2D). TVB-3664 treatment had an adverse
effect and accelerated tumor growth in Pt 2377PT and LM
www.oncotarget.com

Activation of Akt and AMPK pathways
is associated with resistance to TVB-3664
treatment in PDX models and primary CRC
cells
The dependence of tumors on de novo lipid synthesis
for their metabolic requirements, survival and growth
suggests that FASN expression level may determine
a tumors’ response to FASN inhibition [4, 22, 23].
Moreover, our published studies demonstrate that
inhibition of FASN alters multiple signaling pathways
including the Akt and AMPK pathways [6, 8].
To evaluate the correlation between FASN
expression, activation of major oncogenic pathways, and
tumor response in vivo, we analyzed the levels of FASN,
pAkt, pAMPK, pErk1/2, and TIP47 in tumor tissues
from G0 PDX models. Western blot analysis showed
expression of FASN in all established PDXs, with the
highest expression in Pt 2449PT and LM and in Pt 2402.
We found higher levels of pAkt and pAMPK among PDX
models that were resistant to FASN inhibition. The level
of TIP47, a marker for lipid droplets [24], was also higher
in more resistant models (Figure 3A). Pharmacological
inhibition of FASN leads to a decrease in activation of
pAkt [20, 25, 26]. However, inhibition of FASN also
induces pro-survival Akt and ERK signaling in K-Rasdriven cancer cells [27]. To analyze the effect of TVB24790
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Figure 2: Effect of TVB-3664 on tumor growth in CRC PDX models. (A) Schematic representation of study design.

(B) Representative IHC images taken from resected patient tumor tissues stained for FASN expression. (C) PDX models sensitive to
TVB-3664 treatment. Tumor response to FASN inhibition is shown as a fold change in tumor volume over time. Middle row shows
corresponding tumor size at the end of the experiment. Bottom row shows corresponding fold change in weight of animals over time.
Animals were treated daily with 3 mg/kg (Pt 2614 and Pt 2449PT) or 6 mg/kg (Pt 2402 and Pt 2449LM) of TVB-3664 by oral gavage
(*p < 0.05; Pt 2377PT and Pt 2377LM are established from matched primary and liver metastasis tissues from Pt 2377). No response to
TVB-3664 treatment was observed in PDX Pt 2449LM. (D) PDX models resistant to FASN inhibition. Tumor response to FASN inhibition
is shown as a fold change in tumor volume over time. Middle row shows corresponding tumor size at the end of the experiment. Bottom
row shows corresponding fold change in weight of animals over time. Animals were treated daily with 3 mg/kg of TVB-3664 by oral
gavage (*p < 0.05). (E) Accelerated tumor growth in Pt 2377 PDX models treated with 3 mg/kg of TVB-3664. Tumor response to FASN
inhibition is shown as a fold change in tumor volume over time in PDX models established from primary CRC (left) and liver metastasis
tumors (right) Pt 2377. Middle row shows corresponding tumor size at the end of the experiment. Bottom row shows corresponding fold
change in weight of animals over time (*p < 0.05).
www.oncotarget.com
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Table 1: Mutational profile of PDX models
APC
BRAF

KRAS

NRAS

PI3K

EGFR

FGFR

TP53

Pt 93
mut
mut
*
Pt 130
mut
mut
mut
Pt 2449PT
mut
mut
Pt 2449LM
mut
mut
mut
mut
Pt 2402
mut
Pt 2614
mut
mut
mut
Pt 2607
mut
mut
Pt 2568
mut
mut
Pt 2387
mut
mut
mut
mut
Pt 2377PT
mut
mut
mut
Pt 2377LM
mut
mut
mut
Mutational status of 198 cancer genes was assessed in tumor tissues obtained from CRC patients and in established PDX
models and primary cells (*) by NSG sequencing. Mutational status of key oncogenes involved in CRC development and
progression is shown (see Methods).
*

3664 treatment on activity of these pathways, control and
TVB-3664 treated PDX tumors were subjected to western
blot analysis. The response to FASN inhibition was
associated with a decrease in activation of pErk1/2 and
TIP47 and induction of LC3 (an autophagy marker [28])
in the Pt 2402 model (Figure 3B). No significant changes
in pAMPK or pAkt activation were observed in the other
PDX models that were identified as sensitive to FASN
inhibition. In contrast, TVB-3664 treatment induced
activation of pAkt and pAMPK but decreased the level of
TIP47 in the Pt 2387 model (Figure 3C), suggesting that
activation of these pathways may be potential mechanisms
of resistance to FASN inhibition. The analysis of tumor
samples from TVB-3664 treated Pt 2377PT and LM
models showed an increase in pErk1/2 and activation of
pAMPK, respectively (Figure 3D).
All together, these data suggest that activation of
AMPK, Akt and Erk1/2 pathways can be a mechanism of
resistance to FASN inhibition.

metabolomics on tissue samples from Pt 2449PT, Pt 2402,
and Pt 2614, which responded to FASN inhibition. Pt 2449PT
and Pt 2402 mice were fasted 16 h then injected i.p. with
2 g/kg–1 body mass of 13C6-glucose 1 h before sacrifice, as
previously described [29], which allows SIRM tracing of
cellular metabolites in control and treated tumors. Mice with
Pt 2614 tumors were fasted for 16 h but 13C6-glucose labeling
was not performed. To prepare samples for SIRM analysis,
tumor tissues were ground and polar and lipid fractions were
extracted and analyzed using nuclear magnetic resonance and
mass spectrometry.
Analysis of plasma metabolites revealed that
inhibition of FASN in Pt 2449PT and Pt 2402 led to
an increase in 13C labeled glucose and total glucose in
plasma samples of mice treated with TVB-3664 versus
control. In Pt 2614, we observed a significant increase
in the level of acetate (but not glucose) in plasma from
mice treated with TVB-3664, suggesting a different
metabolic response to FASN inhibition in this PDX
model. In contrast to our data from FASN knockdown
cells, no significant changes were observed in the levels
of 13C lactate or total lactate between control and TVB3664 treated groups (Figure 4A); however, we observed a
similar decrease in the lactate to glucose ratio (13C-Lac
/13C-Glc) in Pt 2402 and Pt 2449PT (Figure 4B)
The analysis of FASN-mediated changes in polar
metabolites in tumor tissues showed a significant decrease
in the pool of free adenine nucleotides (ATP + ADP +
AMP = AXP) in all three PDX models analyzed; however,
these changes did not reach statistical significance in the
Pt 2614 model (Figure 4C). Furthermore, inhibition of
FASN significantly decreased the levels of myo-Inositol
(a metabolite that plays an important role in cell signaling
and is a component of structural lipids [30]), in Pt 2402
and Pt 2449PT, but not Pt 2614 (Figure 4D).

Inhibition of FASN is associated with a
significant decrease in a pool of adenine
nucleotides in PDX tumors
Stable knockdown of FASN decreases cellular
respiration and ATP level under metabolic stress conditions in
CRC cell lines [8]. Our studies using HCT116 cells, control
and stable FASN knockdown, labeled with 13C6-glucose for
24 h showed that knockdown of FASN decreases lactate
production by 20% and lowers the lactate to glucose ratio
(by 13C-Lac /13C-Glc) 22% (p = 0.0026). Furthermore,
FASN knockdown decreased the level of excreted lactate
and acetate (p = 0.06) in this cell line (Supplementary
Figure 3A–3D). To investigate the effect of TVB-3664 on
tumor metabolism in PDX tumors, we performed untargeted
www.oncotarget.com
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Together, these data suggest that FASN inhibition is
associated with an increase in glucose metabolism and a
reduction in a pool of adenine nucleotides.

of palmitate in plasma samples collected from control and
TVB-3664 treated mice prior to their sacrifice. Plasma
samples were analyzed by mass spectroscopy as previously
described [6]. We observed a significant decrease in total
palmitate levels in Pt 2402, Pt 2449LM, Pt 2614 and Pt
2377LM but not in others (Figure 5A), suggesting that
there is no correlation between pharmacological inhibition
of FASN and the level of total palmitate in plasma.
Furthermore, we analyzed the lipid fractions extracted
from control and TVB-3664 treated tumors for Pt 2449PT,
Pt 2402 and Pt 2614 models. TVB-3664 treatment led to a
distinct lipid profile in each model as shown by principal
component analysis (Supplementary Figure 4B–4D). The
table of lipid species that significantly changed in each
PDX model is shown in Supplementary Figure 4E. The
binominal analysis of common changes in lipids among
these three PDX models showed that FASN inhibition is
associated with a significant decrease in the levels of fatty
acids and phospholipids such as phosphatidylcholines and
phosphatidic acids and a significant increase in levels of
lactosylceramide and sphingomyelin (Figure 5B, 5C).

Inhibition of FASN leads to significant changes
in lipid composition in CRC
Stable knockdown of FASN is associated with
a significant decrease in de novo palmitate synthesis
[6] and formation of lipid droplets [8], suggesting
that expression of FASN and its activity significantly
affects lipid composition and storage in cancer cells.
Consistently, analysis of HT29 cells (control and stable
FASN knockdown) for incorporation of 13C6-glucose tracer
into lipids showed that inhibition of FASN is associated
with a 40% decrease in de novo synthesized triglycerides
and phospholipids such as phosphatidylethanolamines
and phosphatidylcholines, which are major components
of biological membranes [31] (Supplementary Figure 4A).
To assess the effect of TVB-3664 on lipid
metabolism in PDX models, we first analyzed the levels

Figure 3: Expression of FASN and activation of FASN-associated oncogenic pathways in PDX models. (A) Western blot
analysis of tissues from PDX models (all G1; Pt 2387 G2) showing expression/activation of major oncogenic pathways associated with
de novo lipogenesis. Cases sensitive to FASN inhibition are shown in bold (arrows). (B) Western blot analysis of tumor tissues from Pt
2402 treated with 6 mg/kg of TVB-3664 daily for 5 weeks. (C) Western blot analysis of tissues the Pt 2387 model treated with 3 mg/kg of
TVB-3664 daily for 5 weeks. (D) Western blot analysis of tumor tissues from Pt 2377PT and LM treated with 3 mg/kg of TVB-3664 daily
for 4 weeks.
www.oncotarget.com
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In summary, these data further suggest that anticancer effect of FASN inhibition is associated with a
significant impact on lipid composition.

demonstrates prolonged stable disease when given in
monotherapy and partial response when combined with
paclitaxel in KRASmut non-small cell lung, ovarian, and
breast cancer patients [18]. However, the effect of FASN
inhibition in CRC and potential mechanisms of resistance
to FASN inhibition are still not fully understood. This
study is the first to evaluate the effect of TVB inhibitors in
CRC using PDX models and primary CRC cells.
Evaluation of FASN expression in a CRC tissue
microarray showed that 91% of patients who have
undergone surgery at the University of Kentucky are
positive for FASN expression, which is consistent with
previously published data [34]. All nine PDX models

DISCUSSION
An increase in de novo lipid synthesis is the common
characteristic of many tumors including colorectal
cancer [5]. Inhibition of FASN decreases proliferation
and diminishes metastatic capabilities of cancer cells in
multiple tumor models [4, 6, 18, 32]. Currently, novel
FASN inhibitors developed by 3V-Biosciences are being
evaluated in Phase I/II clinical trial [33]. TVB-2640

Figure 4: Inhibition of FASN alters metabolites levels in PDX models sensitive to TVB-3664. (A) Changes in plasma

metabolites in Pt 2402, Pt 2449PT and Pt 2614 PDXs. (B) Representative figures of NMR spectra obtained from analysis of plasma from
the Pt 2402 model (control vs TVB-3664 treated). Levels of AXP (C) and m-Ins-2 (D) in tumor tissues from PDX models sensitive to
TVB-3664 (p < 0.05) (see Methods).
www.oncotarget.com
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used for evaluation of TVB-3664 in the current study were
positive for FASN expression. Treatment of CRC PDXs
with TVB-3664 as a monotherapy led to a significant
decrease in tumor volume in 30% of cases suggesting
that the presence of FASN expression does not predict
response to FASN inhibitors. The maximum reduction in
tumor weight in response to TVB-3664 treatment achieved
in our study was 50% which is significantly less than the
>80% reduction in tumor growth in non-small-cell lung
cancer PDXs treated with TVB-3166 [12] suggesting that
lung cancer may be more susceptible to FASN inhibition.

Consistent with the study showing variability in
sensitivity to TVB-3166 among 90 cell lines from different
tumor types [12], our in vitro studies demonstrated a
significant variability in responses to FASN inhibition in
CRC. In contrast to reported data from other tumor types
[12, 35], we noted a correlation between high expression
of FASN and increased sensitivity to FASN inhibition in
established CRC cell lines. However, we did not identify a
similar correlation in in vivo studies, suggesting that other
factors such diet and/or the ability of particular tumors to
metabolize endogenous fatty acids may contribute to the

Figure 5: Inhibition of FASN alters lipid composition in PDX models sensitive to TVB-3664. (A) Total plasma palmitate

levels in control and TVB-3664-treated mice measured by mass spectrometry. FA (50 μl of a 1 μM C17) was added to 50 μl of plasma as
an internal standard. Half of each sample was saponificated and derivatized and total palmitate measured by mass spectrometry (*p < 0.05).
(B–C) FASN-mediated changes in lipid classes common among Pt 2402, Pt 2449PT and Pt 2614 PDX models. Lipid classes were evaluated
by grouping the lipids to a class, and within each class setting lipids with fold-change >0 as successes, and <0 as failures, and testing the
ratio of successes to failures to 0.5 using a two-sided binomial test. The reported value for the binomial test is the log-ratio of the calculated
proportion of successes over 0.5 (see Methods).
www.oncotarget.com
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tumor’s response to TVBs as well. Similar to LIM2405,
which was not sensitive to FASN inhibition due to very
low expression of the enzyme in this cell line, low levels
of FASN expression in Pt 2377PT and LM PDXs were
associated with resistance to TVB-3664 and prolonged
treatment led to acceleration of tumor growth. All together,
in vitro and in vivo data suggest that evaluation of FASN
expression is important for selection of candidates to
FASN-targeted therapy, but the tumor being positive for
FASN expression is not sufficient to predict response to
this therapy.
In attempt to correlate the response of FASN
inhibition to the mutational profile of tumors, we
assessed the mutational status of 198 cancer-related
genes. Studies performed by 3V- Biosciences [12] have
shown an association of FASN inhibitor sensitivity with
KRAS mutation status in lung cancer cell lines, but not
in analysis of 29 CRC cell lines. Consistently, we did
not identify any correlation between presence of KRAS
mutation and response to FASN inhibition. Furthermore,
PI3K/Akt signaling has been linked to FASN expression
in many tumor types [26, 27, 36, 37]. Despite the
low number of cases analyzed in this study, we noted
enrichment of mutant PI3K in PDXs resistant to FASN
inhibition. In contrast to the previously published study
which showed no correlation between PI3K status and
CRC cell lines sensitive to FASN inhibition [12], our data
from analysis of cell lines and PDX models treated with
TVB inhibitors suggest that PI3K mutational status and
activation of Akt downstream may affect the response of
CRC cells to FASN inhibition. Our findings are supported
by other reports showing that activation of the PI3K-Akt
axis in response to FASN inhibition may be a potential
mechanism of resistance to FASN inhibition [26, 27]. The
role of PI3K/Akt pathway in resistance to FASN inhibition
is currently being investigated in our laboratory.
Dysregulation of p53 tumor suppressor gene is one of
the most frequent events contributing to transformation of
normal cells to CRC and is associated with the aggressive
and metastatic features of this disease [36]. We noted the
presence of a mutation in TP53 genes in all PDX models
sensitive to FASN inhibition suggesting a potential link
between the TP53 status and the response to TVB-3664.
To investigate other possible markers of FASN
sensitivity, the effect of TVB-3664 on the composition
of metabolites and lipids was analyzed in 3 PDX models
sensitive to FASN inhibition. In agreement with our
reports and others [8, 18, 35], FASN inhibition led to a
decrease in the levels of fatty acids, phospholipids, and
triacylglycerols. Our finding that a high level of TIP47
is associated with resistance to TVB-3664 suggests
that tumors with higher levels of stored lipids are more
resistant to FASN inhibition.
The tumor-suppressing signaling lipid ceramide
is elevated upon FASN inhibition in 231MFP cells [12]
and this is consistent with our data showing increased
www.oncotarget.com

levels of ceramide and hexaceramide in Pt 2402 and Pt
2449PT, respectively. Our results also show an increase
in levels of lactosylceramide and sphingomyelin in TVB3664 sensitive tumors, which has not been previously
reported. Sphingolipids are a class of bioactive lipids that
are key modulators of multiple pathophysiologic processes
including tumorigenesis. Our ongoing studies investigate
the role of FASN-mediated sphingolipid metabolism in
CRC progression and metastasis.
Analysis of metabolites, showing a decrease in
a pool of AXPs and Inositol in TVB-3664 treated PDX
tumors, supports our previously published data that
FASN promotes survival of CRC cells via upregulation of
cellular respiration [8].
Combination of FASN inhibitors with other
therapeutic agents can make cells sensitive to other drugs
or can lead to synergetic effect [18]. Findings in this study
provide evidence of activation of signaling pathways such
as AMPK and Akt in response to FASN inhibition.
Therefore, combination of FASN inhibitors with
inhibitors of Akt or AMPK pathways may be a potential
therapeutic strategy for CRC. Moreover, our studies
suggest that inhibition of de novo fatty acid synthesis
should be combined with dietary changes or with other
therapeutic agents to prevent compensatory mechanisms
by exogenous lipids. A better understanding of the relative
contribution of endogenous and exogenous lipids to
malignant transformation and cancer progression would
further advance the development of new therapeutic
approaches to target lipid metabolism in CRC.

MATERIALS AND METHODS
Colon cancer primary and established cell lines
Primary colon cancer Pt 93, Pt 130 and Pt 2387
cultures were isolated and established from PDX tumors
as previously described [38]. Cells were maintained as
monolayer culture in DMEM supplemented with 10%
FBS (Sigma-Aldrich, St. Louis, MO) and 1% penicillin–
streptomycin.
CRC cell lines were authenticated using STR DNA
profiling in March 2016 (Genetica, Cincinnati, OH).
Primary Pt 93 and Pt 130 cells were authenticated as
unique human cell lines (Genetica). The mutation profiles
of these cell lines were determined using targeted (a panel
of 198 genes) NGS (UKC Genomics_OGSRF). TVB3664, TVB-3166 and TVB-5693 inhibitors were provided
by 3V-Biosciences (Menlo Park, CA). The treatment
regimen for in vitro studies is based on previously
published studies [12, 20].

TMA analysis
Immunoreactivity score of FASN expression was
analyzed in matched normal colon mucosa and tumor
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determined by a two-sided, two-sample t-test with 5%
significance. For combination treatment, statistical
significance was determined based on a one-way ANOVA
with 5% significance. Analysis of tumor volume entailed
a comparison at the last follow-up time using ANOVA
in addition to linear mixed models for analysis of tumor
growth over time and calculation of an adjusted aAUC and
associated confidence interval to quantify tumor growth
inhibition between each treated versus vehicle group. We
employed a linear mixed model with a random effects term
for the PDX model and fixed effects term for treatment
group to perform an overall comparison of tumor volume
across treatment groups and PDX models.

tissues from patients diagnosed with Stage I-IV CRC who
had surgery at UK Chandler Medical Center (TMA ID
BH15991A, n = 57 normal and 56 tumor tissues). Scoring
was carried out blindly by a pathologist. Immunoreactivity
score was determined by multiplication of the values for
staining intensity (0, no staining; 1, weak; 2, moderate; 3,
strong staining) and the values for percentage of positive
tumor cells (0, no positive cells; 1, 0–10%; 2, 11–50%; 3,
51–100% positive).

Tissue collection and in vivo studies
Tissues were obtained from consented patients
with Stage II-IV CRC who had undergone surgery at UK
Medical Center (IRB # 16-0439-P2H). 6–8-week-old
NSG mice (NOD.Cg-Prkdc Il2rg /SzJ) from The Jackson
Laboratory (Bar Harbor, ME, USA) were used for PDX
models. All procedures were performed using protocols
approved by the UK Animal Care and Use Committee.
Briefly, CRC tissues (2–5 mm) obtained from CRC
patients of both sexes were implanted subcutaneously into
their flanks in a small pocket surgically created under the
skin. Established tumors were designated as generation 0
(G0). Tumor tissues from G0 were minced and mixed with
Matrigel to ensure homogeneous distribution of tissues
among mice and allow implantation of an equal volume of
tumor tissues into the flank. To preserve histopathological
and genomic characteristics of clinical CRC tumors and
recapitulate the differential responses of CRC tumors
to FASN inhibitors, all established PDX models were
treated at G1 with exception of the Pt 2387 case, which
was treated at G2. When tumors reached 100 mm3, the
mice were randomized according to animal weight and
tumor size. For evaluation as monotherapy, treatment
(n = 5) and control (n = 5) groups were given TVB-3664
(3–6 µg/kg) vs vehicle (30% PEG400) by oral gavage
daily for 4–6 weeks. Tumors were measured once per
week by a digital caliper and tumor volume was calculated
using the formula: TV = width2 × length × 0.52 as
previously described [12]. Tumor weight was measured at
the end of the experiment. Blood samples were collected
through cardiac puncture at the time of sacrifice.
Mice were fasted and then injected i.p. with 2 g
kg–1 body mass of 13C6-glucose 16 h prior to sacrifice
as previously described [29], to allow SIRM tracing of
cellular metabolites of tumors. 1 h after injection, blood
samples were collected and separated into plasma and
blood cells by centrifugation (4° C, 3,500 × g, 15 min).
Mice were euthanized and tumor tissue was collected for
IHC and flash frozen immediately in liquid N2 for protein
and metabolic analysis.

Tissue extractions for metabolic studies
Frozen tissues were ground in liquid N2 to <10 µm
particles in a 6750 Freezer/Mill (Retsch, Inc., Newtown,
PA) and extracted simultaneously for soluble and lipidic
metabolites as previously described [39].

Nuclear magnetic resonance analysis
NMR spectra were obtained on an Agilent DD2
14.1 T spectrometer equipped with a 3-mm inverse triple
resonance HCN cold probe. The 1D proton spectra were
recorded at 288 k with an acquisition time of 2 s and a
4 s relaxation delay, during which the residual HOD
resonance was irradiated. 1D 1H[13C]HSQC spectra were
recorded with an acquisition time of 0.25 s and a 1.75 s
relaxation delay.
Internal DSS-d6 was used as a chemical shift
reference and for absolute quantification. MNOVA
(Mrestrelab Research, Santiago de Compostela, Spain)
was used for NMR spectral processing. After phasing and
baseline correction, metabolites were quantified using
the peak fitting routines in MNOVA, and assigned using
in-house databases [40]. Isotopomers were quantified
as absolute and fractional enrichments as previously
described [41–43]. Assigned metabolites were normalized
to mg protein determined by BCA analysis.

Fourier transform mass spectrometry (FT-MS)
analysis
A solution of chloroform/methanol (2:1, v/v)
containing 1 mM butylated hydroxytoluene was used to
dissolve the lipid extracts. MS analysis was performed using
an Orbitrap Fusion Tribrid (Thermo Fisher Scientific, San
Jose, CA, USA) attached to a TriVersa NanoMate (Advion
Biosciences, Ithaca, NY, USA) using a “D” electrospray
chip (nozzle inner diameter 4.1 μm) and a cooling unit
to keep the samples at 4° C. For negative and positive
ion mode analysis aliquots of the dissolved lipid extracts
were diluted with methanol and ammonium formate
in 2-propanol/methanol/chloroform. Nanoelectrospray

In vivo data analysis
PDX treatment data are shown as the mean and SD
for the vehicle and TVB groups and statistical significance
www.oncotarget.com
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ionization used 1.6 kV with a 0.6 psi head pressure in
positive ion mode, and 1.5 kV and a 0.5 psi head pressure in
the negative mode. All data were recorded in profile mode
using a 100 ms maximum injection time, automated gain
control at 2.5 × 105, five microscans, and a target resolution
of 450,000 (FWHM at m/z 200). The manufacturer’s default
standard recommendations for the Orbitrap Fusion Tribrid
tuning and calibration was used to achieve a mass accuracy
of 0.5 ppm or less. A previously described software package
developed in-house, Precalculated Exact Mass Isotopologue
Search Engine (PREMISE), was used to make assignments
and the isotopologue distributions for the various lipid
classes [44]. The data were further processed to remove
naturally occurring 13C enrichment in lipid species using
the protocol developed by Moseley [45].

Technologies Inc., Santa Clara, CA). Extracted genomic
DNA was quantified using the Qubit dsDNA HS Assay
(Life Technologies, Illkirch, France). DNA quality was
assessed using the Agilent 2200 TapeStation Genomic
Screentape and reagents (Agilent Technologies Inc., Santa
Clara, CA). Genomic DNA samples (500 ng) were sheared
to fragment sizes of 170–200 base pairs using a Covaris
E220 instrument (Covaris, Woburn, MA). Samples were
adaptor-ligated and amplified for 10 cycles using a
GeneAmp 9700 thermocycler (Applied Biosystems, Foster
City, CA). The DNA was then purified using 1.8× volume
AMPure XP beads (Beckman Coulter, Brea, CA). 750 ng
of each amplified library was hybridized with biotinylated
RNA baits comprising a custom panel of 198 clinically
relevant oncology-related genes (Solid Tumor NGS
Panel v1 Genomics Core Laboratory, UK, Lexington,
KY). The hybridization was run overnight at 65° C and
was followed by DNA capture with streptavidin beads.
Captured libraries were amplified for 12 cycles with
indexing primers and cleaned with 1.8× volume AMPure
XP beads. Libraries are pooled at 4 nM and loaded at 9 pM
onto the HiSeq 2500 as per manufacturer’s instructions for
paired-end sequencing, with a run length of 100 bp.

Metabolic data analysis
Polar fraction analysis: The Wilcoxon rank-sum test
was used to compare the abundance of each metabolite
between TVB and control groups. The method proposed
by Storey et al. [46] was used to adjust for multiple
comparisons and calculate the false discovery rate
q-value. Data analysis was performed using R (version
3.3.1). Metabolites with q-value < 0.05 were considered
statistically significant.

Abbreviations
CRC: Colorectal Cancer; FASN: Fatty Acid
Synthase; LM: Liver Metastasis; NSG: NOD-SCID-IL2rg;
PDX: patient-derived xenograft; PT: Primary Tumor.

Lipid analysis
Assigned positive and negative lipid intensities were
filtered based on HPD sites calculated from the raw peak
lists for each sample. Lipid intensities were normalized
by total intensities in each sample, and log-transformed
after adding a small positive value that was 10e-3 smaller
than the smallest intensity observed. Lipids present in
2/3 of either the control or TVB treated samples were
kept. For each patient, the average log-intensity in the
control samples was subtracted from the control and TVB
samples, resulting in a log fold-change of TVB to control
for a given patient sample.
Individual lipids were evaluated by two-sided t-test
on the TVB samples compared to zero. Lipid classes were
evaluated by grouping the lipids to a class, and within each
class setting lipids with fold-change >0 as successes, and
<0 as failures, and testing the ratio of successes to failures
to 0.5 using a two-sided binomial test. The reported value
for the binomial test is the log-ratio of the calculated
proportion of successes over 0.5. All data processing was
carried out in R 3.3.2.
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